SPDR S&P Biotech ETF Rating $78.14 -2.45 (-3.04%) Closing price 04:10 PM EasternExtended Trading$77.97 -0.17 (-0.21%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.77Holdings in XBI have an aggregate rating of Moderate Buy based on 775 analyst ratings issued in the past year covering 50 companies (77.9% of the portfolio).XBI Aggregate Price Target$78.14High Prediction$78.14Average Prediction$78.14Low Prediction$78.14Holdings in XBI have an aggregate price target of $78.14 and a range of $78.14 to $78.14 covering 50 companies (77.9% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy16 Buy rating(s)Moderate Buy28 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 XBI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.88%ALNYAlnylam Pharmaceuticals$262.16-1.8%4.2828 of 5 stars2.77$316.25 20.6%26Analyst ForecastPositive News2.67%INSMInsmed$73.33-0.1%4.3485 of 5 stars3.00$94.00 28.2%16Positive NewsGap Down2.62%NBIXNeurocrine Biosciences$102.88-5.0%4.8592 of 5 stars2.83$165.38 60.8%23News CoveragePositive NewsGap Down2.60%UTHRUnited Therapeutics$307.36-1.6%4.9047 of 5 stars2.67$388.25 26.3%12News CoveragePositive NewsGap Down2.58%AMGNAmgen$309.85+1.4%4.3709 of 5 stars2.48$314.04 1.4%23Positive News2.56%ABBVAbbVie$201.31-1.9%4.4635 of 5 stars2.92$211.45 5.0%25Insider TradePositive NewsGap Up2.54%GILDGilead Sciences$112.39+0.4%4.5426 of 5 stars2.72$105.12 -6.5%29Positive News2.53%BIIBBiogen$130.71-0.5%4.8702 of 5 stars2.43$213.33 63.2%30Positive News2.53%NTRANatera$138.71-3.1%3.7633 of 5 stars3.00$178.12 28.4%16Insider TradeShort Interest ↑News CoveragePositive NewsGap Down2.53%VRTXVertex Pharmaceuticals$484.01+0.1%3.7626 of 5 stars2.65$509.17 5.2%26Analyst ForecastPositive News2.42%EXASExact Sciences$44.28-0.6%4.4222 of 5 stars2.90$70.26 58.7%21Positive News2.38%REGNRegeneron Pharmaceuticals$610.64-2.4%4.7624 of 5 stars2.76$966.88 58.3%25Analyst ForecastShort Interest ↑Analyst RevisionPositive News2.37%MDGLMadrigal Pharmaceuticals$327.10-2.2%3.5158 of 5 stars2.80$378.44 15.7%10Positive NewsGap Down2.31%INCYIncyte$62.46+0.2%4.6462 of 5 stars2.21$74.88 19.9%19Positive News2.22%BMRNBioMarin Pharmaceutical$67.48-1.2%4.9056 of 5 stars2.71$94.00 39.3%24Analyst DowngradeNews CoveragePositive News2.11%BPMCBlueprint Medicines$87.11-3.2%2.7398 of 5 stars2.70$124.95 43.4%23News CoveragePositive NewsGap Down2.10%MRNAModerna$25.73-7.2%4.3695 of 5 stars2.04$59.00 129.3%24Gap Down2.04%EXELExelixis$36.68-1.0%4.5004 of 5 stars2.50$37.59 2.5%20Analyst RevisionPositive News1.72%TGTXTG Therapeutics$39.34-1.2%2.9657 of 5 stars2.83$40.67 3.4%6News CoveragePositive NewsGap Down1.70%HALOHalozyme Therapeutics$61.92-1.7%4.2002 of 5 stars2.60$62.78 1.4%10Positive News1.67%BBIOBridgeBio Pharma$34.07-1.6%4.5996 of 5 stars2.92$52.64 54.5%12Analyst ForecastOptions VolumeGap Down1.49%SRPTSarepta Therapeutics$58.61-6.2%4.7975 of 5 stars2.83$163.18 178.4%23Quiet Period ExpirationNews CoverageGap UpHigh Trading Volume1.42%CYTKCytokinetics$40.52+0.7%3.978 of 5 stars2.94$82.00 102.4%18Insider TradeAnalyst RevisionNews CoverageGap Down1.38%RVMDRevolution Medicines$32.87-5.0%4.1429 of 5 stars3.08$65.23 98.5%13Analyst ForecastNews CoveragePositive NewsGap Down1.27%IONSIonis Pharmaceuticals$28.52-0.7%4.2548 of 5 stars2.67$58.37 104.7%21Analyst ForecastNews CoverageGap Down1.20%ROIVRoivant Sciences$10.01-0.7%2.3866 of 5 stars3.00$17.50 74.8%4News CoveragePositive NewsGap Down1.19%PCVXVaxcyte$30.56-9.3%2.6501 of 5 stars3.10$136.50 346.7%10Analyst UpgradeAnalyst RevisionNews CoverageGap DownHigh Trading Volume1.19%CRSPCRISPR Therapeutics$32.66-4.5%3.1697 of 5 stars2.48$73.11 123.8%21Gap Down1.19%ALKSAlkermes$31.66-3.0%4.5574 of 5 stars2.69$39.38 24.4%131.17%SWTXSpringWorks Therapeutics$43.07-7.4%1.996 of 5 stars3.00$73.20 70.0%5Positive NewsGap Down1.06%SMMTSummit Therapeutics$18.91-7.6%2.9377 of 5 stars3.00$35.44 87.4%10Gap Down1.06%ADMAADMA Biologics$19.45-3.9%2.3684 of 5 stars3.25$22.50 15.7%4Positive NewsGap Down1.06%VKTXViking Therapeutics$24.22-5.7%4.2878 of 5 stars3.00$95.18 293.0%12Options VolumeGap Down1.04%KRYSKrystal Biotech$178.13-1.6%4.5584 of 5 stars3.00$220.00 23.5%8Positive NewsGap DownHigh Trading Volume1.02%RNAAvidity Biosciences$28.10-5.6%2.5991 of 5 stars3.00$66.69 137.3%13Gap Down0.94%APLSApellis Pharmaceuticals$22.52-2.1%4.4858 of 5 stars2.63$45.59 102.4%19Analyst ForecastAnalyst RevisionNews CoverageGap Down0.93%TWSTTwist Bioscience$37.50-1.9%3.9551 of 5 stars2.70$54.10 44.3%10Positive NewsGap Down0.92%ACLXArcellx$62.44-7.1%2.0568 of 5 stars3.13$108.46 73.7%15Positive NewsGap Down0.87%NUVLNuvalent$68.32-3.0%2.3623 of 5 stars2.91$113.44 66.0%11Positive NewsGap Down0.86%SRRKScholar Rock$30.70-5.7%3.972 of 5 stars3.00$42.67 39.0%6News Coverage0.82%CRNXCrinetics Pharmaceuticals$28.87-8.0%4.4081 of 5 stars2.92$73.00 152.9%13News CoveragePositive NewsGap Down0.80%ACADACADIA Pharmaceuticals$16.12-3.0%3.9903 of 5 stars2.50$23.93 48.5%16Gap Down0.79%SLNOSoleno Therapeutics$72.16-2.0%4.5736 of 5 stars3.22$99.63 38.1%9Analyst ForecastInsider TradeAnalyst RevisionGap Down0.79%VCYTVeracyte$28.47-5.5%4.485 of 5 stars2.70$43.40 52.4%10Positive NewsGap Down0.77%RAREUltragenyx Pharmaceutical$35.13-0.7%4.3801 of 5 stars2.93$92.79 164.1%14News CoverageGap Down0.76%RXRXRecursion Pharmaceuticals$4.81-9.1%2.3031 of 5 stars2.40$8.25 71.5%5Gap Down0.73%RYTMRhythm Pharmaceuticals$49.82-4.1%4.3693 of 5 stars2.92$69.46 39.4%13Gap Down0.72%AKROAkero Therapeutics$39.99-4.7%4.1598 of 5 stars3.00$76.29 90.8%9Positive NewsGap Down0.70%PTCTPTC Therapeutics$46.73-3.4%3.8343 of 5 stars2.53$63.77 36.5%15Analyst ForecastNews CoverageGap Down0.69%BHVNBiohaven$20.52-13.3%3.8846 of 5 stars3.07$62.77 205.8%15Gap DownHigh Trading Volume This page (NYSEARCA:XBI) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XBI Stock Free XBI Stock Alerts